Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	19.98B
Revenue (ttm)	7.28B
Net Income (ttm)	617.06M
Shares Out	20.90M
EPS (ttm)	29.28
PE Ratio	32.66
Forward PE	n/a
Dividend	5.50 (0.58%)
Ex-Dividend Date	Sep 17, 2024

Volume	49,482
Average Volume	48,729
Open	956.00
Previous Close	956.20
Day's Range	942.00 - 974.45
52-Week Range	555.05 - 1,198.25
Beta	0.35
RSI	45.04
Earnings Date	May 16, 2025

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO solutions, including product development, licensing, and commercial manufacturing of complex drugs and dosage forms. It also produces nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprising fixed dosage combinations, fixed dosage plus modifie...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,154
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In 2023, Windlas Biotech's revenue was 6.31 billion, an increase of 22.97% compared to the previous year's 5.13 billion. Earnings were 581.87 million, an increase of 36.51%.